US HB198 | 2023-2024 | 118th Congress
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on January 9 2023 - 25% progression
Action: 2023-01-20 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on January 9 2023 - 25% progression
Action: 2023-01-20 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To increase reporting requirements and transparency requirements in the 340B Drug Pricing Program, and for other purposes.
Title
Drug Pricing Transparency and Accountability Act
Sponsors
Rep. Matt Rosendale [R-MT] |
History
Date | Chamber | Action |
---|---|---|
2023-01-20 | House | Referred to the Subcommittee on Health. |
2023-01-09 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2023-01-09 | House | Introduced in House |
Subjects
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/118th-congress/house-bill/198/all-info |
Text | https://www.congress.gov/118/bills/hr198/BILLS-118hr198ih.pdf |